ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Public health and primary care · PLoS Med · 2026-02-10

Phase 4 RCT in 500 people with TB exposure and latent infection in Brazil: completion was 89.6% with 1HP vs 84.1% with 3HP (not significant); targeted safety events or discontinuation were 16.1% vs 10.4% (p=0.05). Neither regimen was superior.

RCTn = 500
Durovni et al. Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial
Infectious diseases · Lancet HIV · 2026-02-06

Phase 3 non-inferiority RCT in 205 Ugandan adults with advanced HIV and cryptococcal meningitis: starting 1HP before discharge was non-inferior to outpatient start for TB-free survival plus completion at 18 weeks (70% vs 62%); grade 4 anaemia was rarer (2% vs 9%).

Clinical trialn = 205
Ellis et al. Inpatient initiation of tuberculosis preventive therapy with 1 month of isoniazid and rifapentine for adults with advanced HIV disease and cryptococcal meningitis (IMPROVE): a non-inferiority, randomised controlled trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.